{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:08:52Z","timestamp":1792638532586,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017689","name":"Guangdong Provincial People's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jconrel.2026.114747","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T23:33:07Z","timestamp":1771716787000},"page":"114747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"393","author":[{"given":"Yi-Chen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lv","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114747_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114747_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030459","article-title":"Optimizing Osimertinib for NSCLC: targeting resistance and exploring combination therapeutics","volume":"17","author":"Liao","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2026.114747_bb0015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jtho.2024.12.027","article-title":"A prospective phase II trial of first-line osimertinib for patients with EGFR mutation-positive NSCLC and poor performance status (OPEN\/TORG2040)","volume":"20","author":"Fukui","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030841","article-title":"Osimertinib resistance: molecular mechanisms and emerging treatment options","volume":"15","author":"Gomatou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2026.114747_bb0025","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (review)","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0030","article-title":"Consensus on the lung cancer management after third-generation EGFR-TKI resistance","volume":"53","author":"Zhou","year":"2024","journal-title":"Lancet Reg. Health West. Pac."},{"key":"10.1016\/j.jconrel.2026.114747_bb0035","doi-asserted-by":"crossref","first-page":"LB458","DOI":"10.1158\/1538-7445.AM2025-LB458","article-title":"Osimertinib treatment drives expression of TROP2, and combination treatment with datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, enhances its efficacy in PDX models of EGFR mutant non small-cell lung cancer","volume":"85","author":"Matthew","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3161","article-title":"Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC","volume":"40","author":"Janne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung Cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2026.114747_bb0055","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jconrel.2026.114747_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03638-2","article-title":"Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials","author":"Zhao","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.114747_bb0065","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of Patritumab Deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung Cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","author":"Horinouchi","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0075","doi-asserted-by":"crossref","first-page":"S759","DOI":"10.1016\/j.annonc.2023.09.2352","article-title":"1318MO first-in-human study of ABBV-637, an EGFR-targeting BCL-XL\u2014inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed\/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"34","author":"Rotow","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102902","article-title":"Antibody-drug conjugates in NSCLC with actionable genomic alterations: optimizing smart delivery of chemotherapy to the target","volume":"134","author":"Mountzios","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2026.114747_bb0085","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2026.114747_bb0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114747_bb0130","first-page":"329","article-title":"Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine","volume":"7","author":"Sadeghi","year":"2014","journal-title":"Pharmgenom. Pers. Med."},{"key":"10.1016\/j.jconrel.2026.114747_bb0145","first-page":"103","article-title":"Spotlight on trastuzumab deruxtecan (DS-8201,T-DXd) for HER2 mutation positive non-small cell lung cancer","volume":"12","author":"Azar","year":"2021","journal-title":"Lung Cancer (Auckl.)"},{"key":"10.1016\/j.jconrel.2026.114747_bb0155","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","article-title":"SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1\/2 study","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114747_bb0165","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-Met antibody-drug conjugate that targets both MET-amplified and c-met-overexpressing tumors, irrespective of MET pathway dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102393","article-title":"A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)","volume":"106","author":"Abuhelwa","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2026.114747_bb0175","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2025.43.16_suppl.8512","article-title":"Telisotuzumab adizutecan (ABBV-400; Temab-a), a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): results from a phase 1 study","volume":"43","author":"Camidge","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0180","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1200\/JCO.2025.43.16_suppl.8592","article-title":"RC108 in combination with furmonertinib in patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) with MET overexpression: results from a phase Ib\/II trial","volume":"43","author":"Liu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0095","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.114747_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28385","article-title":"Datopotamab deruxtecan: a novel antibody drug conjugate for triple-negative breast cancer","volume":"10","author":"Schipilliti","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2026.114747_bb0210","author":"US Food and Drug Administration"},{"key":"10.1016\/j.jconrel.2026.114747_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0240","author":"Jiataile"},{"key":"10.1016\/j.jconrel.2026.114747_bb0490","author":"National Medical Products Administration"},{"key":"10.1016\/j.jconrel.2026.114747_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100790","article-title":"Targeting HER3 for cancer treatment: a new horizon for an old target","volume":"8","author":"Uliano","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.jconrel.2026.114747_bb0265","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","article-title":"A novel HER3-targeting antibody\u2013drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization","volume":"25","author":"Hashimoto","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0285","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4143\/crt.2024.714","article-title":"The era of antibody drug conjugates in lung cancer: trick or threat?","volume":"57","author":"Riudavets","year":"2025","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2026.114747_bb0305","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0350","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT008","article-title":"Abstract CT008: first-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors","volume":"85","author":"Lu","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0105","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0110","article-title":"Clinical pharmacology of antibody-drug conjugates","volume":"10","author":"Mahmood","year":"2021","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jconrel.2026.114747_bb0115","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.114747_bb0120","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0150","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jtho.2024.09.082","article-title":"OA16.05 Trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing nonsquamous non-small cell lung cancer: DESTINY-Lung03 part 1","volume":"19","author":"Planchard","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0215","doi-asserted-by":"crossref","first-page":"S1630","DOI":"10.1016\/j.annonc.2024.10.656","article-title":"LBA7 efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): a pooled analysis of TROPION-Lung01 and TROPION-Lung05","volume":"35","author":"Ahn","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085680","article-title":"Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial","volume":"389","author":"Fang","year":"2025","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jconrel.2026.114747_bb0245","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114747_bb0270","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.annonc.2024.02.003","article-title":"Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC","volume":"35","author":"Yu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0275","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2025.43.16_suppl.8506","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated EGFR advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0280","author":"Merck"},{"key":"10.1016\/j.jconrel.2026.114747_bb0290","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1016\/j.annonc.2024.08.709","article-title":"642P phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC","volume":"35","author":"Zhou","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0315","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jtho.2025.09.063","article-title":"OA10.03 phase I\/II study of Iza-Bren (BL-B01D1) as monotherapy in patients with locally advanced or metastatic EGFR mutated NSCLC","volume":"20","author":"Fang","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0320","author":"Bristol Myers Squibb"},{"key":"10.1016\/j.jconrel.2026.114747_bb0495","author":"Chinese Clinical Trial Registry"},{"key":"10.1016\/j.jconrel.2026.114747_bb0140","article-title":"Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR mutation-positive NSCLC","volume":"4","author":"Jebbink","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.jconrel.2026.114747_bb0220","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1556-0864(25)00196-0","article-title":"1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD","volume":"20","author":"Le","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jtho.2019.09.006","article-title":"Exon 16\u2013skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R\/T790M\u2013positive non\u2013small cell lung cancer","volume":"15","author":"Hsu","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0135","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.114747_bb0160","first-page":"15","article-title":"MET overexpression and gene amplification in NSCLC: a clinical perspective","volume":"4","author":"Landi","year":"2013","journal-title":"Lung Cancer (Auckl.)"},{"key":"10.1016\/j.jconrel.2026.114747_bb0185","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/2159-8290.CD-24-1515","article-title":"Eradicating drug tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy","volume":"15","author":"Baldacci","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2026.114747_bb0190","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.7150\/jca.57711","article-title":"Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment","volume":"12","author":"Sun","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.jconrel.2026.114747_bb0195","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jtho.2024.09.143","article-title":"MA07.06 eradicating drug tolerant persisters (DTPs) in EGFR-mutated non small cell lung cancer (NSCLC) by targeting TROP2","volume":"19","author":"Baldacci","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0205","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1158\/1538-7445.AM2023-4893","article-title":"Abstract 4893: evaluation of bystander antitumor effect of Dato-DXd in TROP2 (+) and TROP2 (\u2212) lung cell lines admixed tumor xenograft mouse models","volume":"83","author":"Yasuda","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0225","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1556-0864(25)00319-3","volume":"20","author":"Nadal","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0230","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0250","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/0008-5472.CAN-21-2426","article-title":"EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody-drug conjugate HER3-DXd","volume":"82","author":"Haikala","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0255","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.CCR-21-3359","article-title":"HER3 augmentation via blockade of EGFR\/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non-small cell lung cancer","volume":"28","author":"Yonesaka","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0295","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0300","first-page":"18","article-title":"Biology drives the discovery of bispecific antibodies as innovative therapeutics","volume":"3","author":"Nie","year":"2020","journal-title":"Antib. Ther."},{"key":"10.1016\/j.jconrel.2026.114747_bb0310","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1158\/1538-7445.AM2023-2642","article-title":"Abstract 2642: BL-B01D1, a novel EGFR\u00d7HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation","volume":"83","author":"Wan","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0325","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0330","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0335","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11684-022-0951-0","article-title":"Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors","volume":"16","author":"Sun","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.jconrel.2026.114747_bb0340","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41419-024-06940-y","article-title":"Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer","volume":"15","author":"Izumi","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2026.114747_bb0345","article-title":"Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer","volume":"23","author":"Lu","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2026.114747_bb0355","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.2025.43.16_suppl.107","article-title":"Phase 1 trial of SHR-A2102, a nectin-4\u2013directed antibody drug conjugate (ADC), in advanced solid tumors","volume":"43","author":"Zhong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0360","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1158\/1538-7445.AM2023-5736","article-title":"Abstract 5736: AZD9592: an EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond","volume":"83","author":"Comer","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0375","doi-asserted-by":"crossref","first-page":"S804","DOI":"10.1016\/j.annonc.2024.08.1312","article-title":"1255MO a phase II safety and efficacy study of PM8002\/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"35","author":"Wu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0380","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251405044","article-title":"Antibody-drug conjugates outperform chemotherapy in EGFR TKI-resistant NSCLC: a Bayesian network meta-analysis","volume":"17","author":"Chen","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0385","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/j.jtho.2023.09.595","article-title":"P2.09-21 VRN110755, a new therapeutic option for EGFR mutation-driven NSCLC with brain metastasis or 1st-line osimertinib-resistant EGFR mutations","volume":"18","author":"Jung","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0390","doi-asserted-by":"crossref","first-page":"8593","DOI":"10.1200\/JCO.2024.42.16_suppl.8593","article-title":"Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced\/metastatic non-small cell lung cancer (a\/m NSCLC) with actionable genomic alterations (AGA): results from TROPION-Lung05","volume":"42","author":"Lisberg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0395","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(25)00465-6","article-title":"Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Fuereder","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0400","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","article-title":"Treatment-related adverse events of antibody drug-conjugates in clinical trials","volume":"18","author":"Tan","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0405","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251324889","article-title":"Toxicities and management strategies of emerging antibody\u2013drug conjugates in breast cancer","volume":"17","author":"Kang","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0410","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114747_bb0415","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2026.114747_bb0425","first-page":"304","article-title":"Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)","volume":"46","author":"Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.jconrel.2026.114747_bb0430","doi-asserted-by":"crossref","DOI":"10.59717\/j.xinn-med.2023.100018","article-title":"A new perspective in the research of antibody drug conjugate","volume":"1","author":"Li","year":"2023","journal-title":"Innov. Med."},{"key":"10.1016\/j.jconrel.2026.114747_bb0435","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2014-0234","article-title":"Oncogenic alterations in ERBB2\/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin","volume":"20","author":"Chmielecki","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2026.114747_bb0440","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.tips.2025.10.005","article-title":"Artificial intelligence in antibody-drug conjugate development","volume":"46","author":"Wang","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2026.114747_bb0445","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41523-023-00605-3","article-title":"Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer","volume":"10","author":"Guerriero","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.jconrel.2026.114747_bb0450","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114747_bb0455","article-title":"Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors","volume":"11","author":"Guo","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.jconrel.2026.114747_bib535","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41587-024-02143-0","article-title":"A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models","volume":"43","author":"Ren","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114747_bib536","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/j.cell.2024.03.039","article-title":"IGSF8 is an innate immune checkpoint and cancer immunotherapy target","volume":"187","author":"Li","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114747_bb0460","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/1538-7445.AM2024-1871","article-title":"Abstract 1871: Discovery and characterization of NXV01c, an EGFR \u00d7 cMET bispecific nanobody drug conjugate with potent anti-tumor activity","volume":"84","author":"Wu","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jconrel.2026.114747_bb0465","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1158\/1538-7445.AM2025-7149","article-title":"Abstract 7149: The role of TROP2 in the MoA of Dato-DXd and how it underpins the biologic rationale of the novel AI-guided biomarker TROP2 normalized membrane ratio","volume":"85","author":"Sung","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114747_bb0470","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0500","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0505","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0510","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0515","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0520","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0525","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0530","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0475","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.114747_bb0480","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.114747_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189369","article-title":"Sequencing of antibody drug conjugates in breast cancer: evidence gap and future directions","volume":"1880","author":"Pacholczak-Madej","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:58:28Z","timestamp":1781715508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926001495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":106,"alternative-id":["S0168365926001495"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114747","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114747"}}